Tocilizumab, a humanized monoclonal antibody, selectively targets the interleukin-6 receptor (IL-6r) [1, 2] and is reported safe and effective in other settings such as after chimeric antigen receptor (CAR)-T-cell therapy, rheumatoid arthritis, and giant cell arteritis [3, 4]. This evidence concerns the gene IL6R and rheumatoid arthritis.